FDA Approves Subcutaneous Pembrolizumab for Cancer Treatment
The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of pembrolizumab, also known as Keytruda, marking a significant advancement in cancer treatment. Announced on September 19, 2025,…